Yonsei Med J.  2007 Apr;48(2):171-175. 10.3349/ymj.2007.48.2.171.

Clinical Role of Bone Marrow Angiogenesis in Childhood Acute Lymphocytic Leukemia

  • 1Department of Pediatrics, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • 2Cancer Metastasis Research Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • 3Department of Pediatrics, College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Korea. wonsc@caumc.or.kr


Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are associated with increased angiogenesis, growth, and metastasis in solid tumors. But, until today, the importance of theses factors on leukemia, especially childhood acute lymphocytic leukemia (ALL) has received limited attention. Therefore, this study examined the bone marrow plasma VEGF and bFGF levels in ALL patients and normal controls. PATIENTS AND METHODS: Bone marrow plasmas at diagnosis from 33 ALL patients (median age 5.9 years; range 1.8-13.9 years) were used for analysis. The bone marrow levels of bFGF and VEGF were determined by enzyme-linked immunosorbent assay (R & D Systems) and compared with the bone marrow levels of 7 healthy control subjects (median age 11.98 years; 6 months -13.6 years). RESULTS: Average VEGF was higher in relapse ALL (N=7, 216.6 +/- 79.9pg/mL) compared to standard (N=9, 36.8 +/- 12.1pg/mL) (p=0.013) or high risk ALL (N=17, 80.0 +/- 12.2pg/mL) (p=0.023). bFGF levels were also significantly higher in relapse than standard-, or high-risk ALL patients (relapse ALL; 48.6 +/- 15.4pg/mL, standard risk ALL; 18.9 +/- 5.5pg/mL, high risk ALL; 19.0 +/- 3.5pg/mL, normal control; 18.6 +/- 4.0pg/mL) (p=0.003). Three patients with refractory relapse and death had much higher VEGF and bFGF values (VEGF; 420.0 +/- 81.6pg/ mL, bFGF; 85.6 +/- 3.2pg/mL). CONCLUSION: Our data suggest that the increased levels of VEGF and bFGF in bone marrow may play an important role in prognosis of childhood ALL.


Angiogenesis factor; child; acute lymphocytic leukemia


  • Fig. 1 Bone marrow plasma VEGF (A) and bFGF (B) levels at time of diagnosis for acute lymphocytic leukemia (ALL) patients and normal controls. VEGF, vascular endothelial growth factor; bFGF, basic fibroblastic growth factor; *p>0.05; †p<0.05.


1. Orpana A, Salven P. Angiogenic and lymphangiogenic molecules in hematological malignancies. Leuk Lymphoma. 2002. 43:219–224.
2. Ribatti D, Scavelli C, Roccaro AM, Crivellato E, Nico B, Vacca A. Hematopoietic cancer and angiogenesis. Stem Cells Dev. 2004. 13:484–495.
3. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol. 2003. 45:227–244.
4. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005. 23:1011–1027.
5. Gerber HP, Ferrara N. The role of VEGF in normal and neoplastic hematopoiesis. J Mol Med. 2003. 81:20–31.
6. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005. 105:1383–1395.
7. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997. 150:815–821.
8. Koomagi R, Zintl F, Sauerbrey A, Volm M. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res. 2001. 7:3381–3384.
9. Pule MA, Gullmann C, Dennis D, McMahon C, Jeffers M, Smith OP. Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance. Br J Haematol. 2002. 118:991–998.
10. Faderl S, Do KA, Johnson MM, Keating M, O'Brien S, Jilani I, et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood. 2005. 106:4303–4307.
11. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000. 95:309–313.
12. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000. 96:2240–2245.
13. Schneider P, Vasse M, Legrand E, Callat MP, Vannier JP. Have urinary levels of the angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, a prognostic value in childhood acute lymphoblastic leukaemia? Br J Haematol. 2003. 122:163–164.
14. Yetgin S, Yenicesu I, Cetin M, Tuncer M. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2001. 42:83–88.
15. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997. 94:663–668.
16. Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology. 2000. 58:169–174.
Full Text Links
  • YMJ
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr